XGN:NASDAQExagen Inc. Analysis

Exagen Inc. (XGN) posted a near 20% revenue increase in 2025, driven by higher testing volumes and strategic expansions, yet it remains loss‑making with operating and profit margins around –30% and negative cash flows. The stock trades at a forward P/E of –6.6, a price‑to‑sales of 1.07 and a price‑to‑book of 3.87, while analysts are overwhelmingly bullish – over 80% maintain “Buy” ratings and the consensus target price implies a ~194% upside. Technical signals are mixed: the 20‑day SMA (≈$2.94) sits just below the current price, the 50‑day SMA is higher (≈$3.03) indicating short‑term pressure, and the MACD histogram turned positive, giving a bullish signal despite an overall bearish trend direction. Volatility is extreme at >55% over the past 30 days and beta of 1.44 points to heightened market sensitivity.
Bottom line: the company’s growth narrative and lofty upside potential are offset by deep profitability challenges, a fragile balance sheet, and a volatile price profile, suggesting a cautious but potentially rewarding play for investors willing to tolerate risk.